Global Value Equity Fund

Capital at risk. Past performance is not a reliable indicator of current or future results and should not be the sole factor of consideration when selecting a product or strategy.

The listed funds are not an exhaustive list of funds available. Visit www.funds.troweprice.com to see the full range of funds offered by T. Rowe Price, including those that consider environmental and social characteristics as part of their investment process. For up to date information regarding any T. Rowe Price fund's investment strategy, please see the relevant fund KID and prospectus.

Overview

Manager's Outlook

Investors have had to radically reappraise their outlook for the paths of interest rates and inflation, and the accompanying impact on markets and economies. As we noted earlier in this report, over the last nine months or so by increasing the allocation to more defensive parts of the value universe we have implemented a more balanced profile in the portfolio, and we believe that this is currently appropriate given the current material uncertainties. Valuation spreads in the marketplace remain reasonable and relative valuations of value versus growth are relatively attractive versus history, but both suggest a more subdued value opportunity set than the abundant situation of one-to-two years' ago. There may also be scope for market worries on rates and inflation to subside somewhat.

A changed landscape is possible over the next decade ? materially higher levels of capital expenditure may be required to address the capacity requirements in many industries as a result of both the desired decarbonization of industries and economies as well respond to threats posed to supply chains, specifically in energy but also more broadly as "deglobalization" may well continue. Further, governments may be more willing in engage in higher levels of fiscal spending to meet future economic shocks and fulfil a social agenda, and electorates have seen how effective such spending can (appear to) be within the pandemic. This combination of both higher capex and fiscal spending is likely to be beneficial, in our view, not only to many value-oriented companies but is also likely to put ongoing upwards pressure on inflation and interest rates.

�

In the U.S., we continue find opportunities in well-run, quality companies but are mindful of valuations. The health care sector provides ample strong ideas for the long-term. European economies have been more deeply impacted by Russia's invasion of Ukraine and we find more dislocation in these markets. Fiscal stimulus measures continue to be rolled out and monetary policy remains accommodative. Plans are progressing for the Next Generation European Union (EU) Fund, which aims to support EU member countries in their recovery from the impacts of the pandemic. We continue to find opportunities in companies with more cyclical characteristics, which we believe stand to emerge on the other side of the pandemic in positions of strength, as well as defensive names that offer some level of protection in a market downturn.

�

We have become incrementally more cautious on the near-term outlook for Japan but remain optimistic. There has been significant fiscal stimulus response to aid the economic recovery. Crucially for investors in the market, corporate governance in Japan has been improving in recent years, with companies becoming more shareholder friendly. We continue to identify stocks with compelling valuations befitting of our value perspective.

�

Elsewhere in Asia, we continue to uncover ample compelling opportunities in China's broad market, despite market setbacks in recent months. Concerns over regulatory developments, on-off domestic movement restrictions, and continued strict restrictions on international travel, have all weighed on stock prices in recent months. However, our well-resourced research team finds plenty of opportunities in good companies with compelling valuations.

�

We concentrate on the bottom-up view and our strategy continues to invest across the value spectrum in the best ideas from our global research platform. We aim to balance our exposure to economically sensitive and "deep value" names; also holding companies with strong free cash flow generation not yet fully appreciated by the market and with the scope to increase shareholder returns; as well as looking for pockets of controversy where fundamentally sound, well-run businesses face unwarranted investor skepticism. Given our robust research platform and collective experience, we are confident in our ability to find these unique opportunities before their potential for substantial prosperity becomes obvious to other investors.

�

Strategy

Fund Summary

We employ a relative value approach that looks holistically across the value spectrum to identify companies with durable free cash flows that are not fully appreciated by the market. We aim to maintain a core portfolio of quality companies but will also pursue attractive risk/reward opportunities in out-of-favour cyclical companies and deep-value turnaround situations. The promotion of environmental and/or social characteristics is achieved through the fund's commitment to maintain at least 10% of the value of its portfolio invested in Sustainable Investments, as defined by the SFDR. Additionally, we apply a proprietary responsible screen (exclusion list). The manager is not constrained by the fund’s benchmark, which is used for performance comparison purposes only.

OUR VIEWS ON GLOBAL EQUITIES

Performance - Net of Fees

Past performance is not a reliable indicator of future performance.

29-Feb-2024 - Sebastien Mallet, Portfolio Manager,

Global equities registered positive returns in February on the back of slowing inflation and strong economic data in the US. However, concerns that interest rates may remain higher for longer curbed gains. Within the portfolio, stock picks and our underweight allocation to consumer discretionary hurt relative returns. Here, shares of a Japanese consumer electronics company lost ground after it reported below-consensus third-quarter results due to weaker demand in its small- to medium-sized displays. The firm downgraded its full-year earnings guidance which added to investor caution. Security selection in materials and health care also hindered. Conversely, utilities was the top-contributing sector due to our stock picks, followed by financials and energy. At the country level, our stock choices in Japan and the Netherlands held back relative performance. In contrast, our investments in Switzerland and Australia helped. In the former, an insurance products and services provider registered gains on the back of encouraging earnings that showed better-than-expected operating profits in 2023. Shares were also propped up by news that the company will raise its dividends and share buybacks. Stock selection in Germany also benefitted.

30-Jun-2022 - Sebastien Mallet, Portfolio Manager, Global Value Equity Fund,

Over the course of 2021 we began to shift the portfolio to a more neutral/balanced stance by increasing our allocation to our defensive holdings. In early 2022, we continued to reduce the cyclical exposure and by the end of the second quarter, the portfolio was broadly balanced between defensive and cyclical names.� �On a sector basis, we added to health care and IT, as well as marginally increasing our energy exposure.� We trimmed our financials holding while also reducing our communication services holdings.� We also made a number of changes within our industrials and business services holdings.

�

At the end of June, our largest overweight sector positions were in health care, utilities, and financials while the largest underweight sector positions included IT and consumer discretionary. On a geographic basis, we remain cautious about valuations in the U.S. Although the country represents the largest position in the portfolio on an absolute basis, we retain a significant relative underweight. Despite this, we made a number of adjustments in this large market, eliminating holdings where our investment case no longer held or where valuations had become less compelling as well as adding new positions where we identified compelling reasons for investing.

On a country basis, our largest relative overweight positions by the end of June were in China, the Netherlands, and Japan. Valuations in China are attractive, in our view, but we are mindful of geopolitical and regulatory risk. We raised our exposure over the review period and are hopeful that the regulatory crackdown is largely behind us and many stocks in this market are trading below their cash/book value. In Japan, we are seeing continued signs of improving corporate governance, however macroeconomic and currency concerns weigh on sentiment. We reduced our exposure to the country over the review period. Within emerging markets, we see interesting investment opportunities in India but this is an expensive market.

Financials

We retain our overweight position in financials but decreased the extent of this position over the quarter. Over the past year we have become incrementally more cautious on some of our U.S. positions and have shifted our exposure within this space. In the second quarter we reduced our exposure to U.S. banks as we believe opportunities are more attractive elsewhere in the sector, namely insurers. Our broad-based move out of U.S. banks has now largely played out. We are worried about the credit cycle and believe it is too early to buy back into the sector.

We eliminated the holding in U.S.-based Huntington Bancshares, a diversified large regional bank as we felt the valuation was beginning to price in higher interest rates. The U.S. bank has one of the more cautious interest rate risk strategies amongst peers.
We sold out of our position in Equitable Holdings, a large financial services company whose main business is life insurance. Although U.S. insurers as a group still have good pricing power and will likely benefit from higher interest rates, the sector was looking expensive in our view. In addition, we had concerned that Equitable is very sensitive to equity market movements.
We used part of the proceeds of these sales to purchase a position in Ping An Insurance Group, the largest insurer in China by market capitalization. The company trades at a very low valuation in both absolute terms and on a historical basis following a sharp decline in value of new business (VNB) in 2019.� Our investment thesis is that VNB will gradually accelerate within the next three-to-five years, which should drive a re-rating of the stock.

Health Care

The portfolio has an overweight position in the health care sector, reflecting our preference for defensive sectors currently, and we raised our exposure further. Over the quarter, we identified a new opportunity in the U.S. and in France. Last year, in 2021, as the country's economy reopened and investors focused on cyclical growth stocks, health care stocks were left behind; we believe valuations have now reached very attractive levels and the sector looks cheap. Uncertainty over health care reforms in the U.S by the Biden administration have also weighed on the sector, despite the fact that this space is home to many companies with good growth prospects. Our bias remains to high-quality names.

We bought a position in Johnson & Johnson, a diversified health care company engaged in the development, manufacturing and sale of pharmaceuticals, medical devices, and consumer health care products. Its share price has de-rated due to the ongoing mix shift towards pharmaceuticals. However, the majority of its key franchises have begun to show significant recoveries from the impact of COVID-19 and we expect this trend to continue.
Sanofi is France-based diversified multinational health care company, which is engaged in the development, manufacturing and sale of pharmaceuticals, vaccines, and over-the-counter (OTC) health care products. Sentiment towards the name has been held back recently by disappointing trial results from its drug to fight breast cancer, leading investors to question Sanofi's R&D capabilities. We initiated a position in Sanofi as we believe the company has a number of promising drugs in the pipeline, including treatments for hemophilia and multiple sclerosis.
We largely funded these purchases through our elimination of Roche Holding; we believe the company is fully valued at present and it has a number of drugs going off-patent within the next few years.

IT

IT remains the portfolio's largest relative underweight sector position. However, at a global level the sector sold off very sharply over the quarter, leading us to identify what we believe to be compelling investment opportunities within this space. As a result, our relative weighting to the sector increased.

We initiated a position in FPT, a Vietnam-based IT services company. The Vietnamese stock market fell sharply in April and May and we felt some valuations had reached attractive levels. We believe the company's long-term growth potential is materially better than what current valuation multiples imply. Country-specific factors support the company, in our view, driving a cost advantage versus global competition and favorable pricing for its customers. Vietnam also hosts an IT-relevant labor pool that is undergoing rapid development which is, in turn, key to the company's growth runway.
Broadcom is a U.S.-based semiconductor company that makes products for the�wireless and broadband communication industry. We bought a position in the company because the stock offers an attractive free cash flow yield and, in our view, the company's earnings durability and growth are underappreciated by the market.

Japan

On a country basis we reduced our exposure over the quarter although retain a modest overweight. This is partly due to bottom-up stock-specific factors but we are also concerned by the impact of a yen and the slow pace of change at a corporate level.

We eliminated the holding in Keisei Electric Railway. We had bought the stock on expectations of meaningful capital allocation changes among Japan's railway companies, but this investment thesis has not played out and we cut our position to invest in more compelling opportunities elsewhere.
We sold out of our position in Panasonic. Our investment case was for it to increase its electric battery (EV) capacity and for this business to become a significant profit contributor. However, this turnaround has not taken place and we believe the pace and magnitude of the EV battery business expansion is unlikely to be as good as we previously believed. We exited our position.

31-Jan-2024 - Sebastien Mallet, Portfolio Manager,

In our view, market worries about interest rates and inflation could subside as major central banks, namely the US Federal Reserve, appear to be near a peak in their interest rate-hiking cycles. As a result, we have started to identify opportunities in the more cyclical and deep value areas of the value space. With this in mind, we have relative overweight positions in financials as well as the traditionally more defensive health care and utilities sectors. While we have increased our exposure to information technology, we remain largely underweight relative to the benchmark.

30-Jun-2022 - Sebastien Mallet, Portfolio Manager, Global Value Equity Fund,

We eliminated the holding in U.S.-based Huntington Bancshares, a diversified large regional bank as we felt the valuation was beginning to price in higher interest rates. The U.S. bank has one of the more cautious interest rate risk strategies amongst peers.
We sold out of our position in Equitable Holdings, a large financial services company whose main business is life insurance. Although U.S. insurers as a group still have good pricing power and will likely benefit from higher interest rates, the sector was looking expensive in our view. In addition, we had concerned that Equitable is very sensitive to equity market movements.
We used part of the proceeds of these sales to purchase a position in Ping An Insurance Group, the largest insurer in China by market capitalization. The company trades at a very low valuation in both absolute terms and on a historical basis following a sharp decline in value of new business (VNB) in 2019.� Our investment thesis is that VNB will gradually accelerate within the next three-to-five years, which should drive a re-rating of the stock.
We bought a position in Johnson & Johnson, a diversified health care company engaged in the development, manufacturing and sale of pharmaceuticals, medical devices, and consumer health care products. Its share price has de-rated due to the ongoing mix shift towards pharmaceuticals. However, the majority of its key franchises have begun to show significant recoveries from the impact of COVID-19 and we expect this trend to continue.
Sanofi is France-based diversified multinational health care company, which is engaged in the development, manufacturing and sale of pharmaceuticals, vaccines, and over-the-counter (OTC) health care products. Sentiment towards the name has been held back recently by disappointing trial results from its drug to fight breast cancer, leading investors to question Sanofi's R&D capabilities. We initiated a position in Sanofi as we believe the company has a number of promising drugs in the pipeline, including treatments for hemophilia and multiple sclerosis.
We largely funded these purchases through our elimination of Roche Holding; we believe the company is fully valued at present and it has a number of drugs going off-patent within the next few years.
We initiated a position in FPT, a Vietnam-based IT services company. The Vietnamese stock market fell sharply in April and May and we felt some valuations had reached attractive levels. We believe the company's long-term growth potential is materially better than what current valuation multiples imply. Country-specific factors support the company, in our view, driving a cost advantage versus global competition and favorable pricing for its customers. Vietnam also hosts an IT-relevant labor pool that is undergoing rapid development which is, in turn, key to the company's growth runway.
Broadcom is a U.S.-based semiconductor company that makes products for the�wireless and broadband communication industry. We bought a position in the company because the stock offers an attractive free cash flow yield and, in our view, the company's earnings durability and growth are underappreciated by the market.
We eliminated the holding in Keisei Electric Railway. We had bought the stock on expectations of meaningful capital allocation changes among Japan's railway companies, but this investment thesis has not played out and we cut our position to invest in more compelling opportunities elsewhere.
We sold out of our position in Panasonic. Our investment case was for it to increase its electric battery (EV) capacity and for this business to become a significant profit contributor. However, this turnaround has not taken place and we believe the pace and magnitude of the EV battery business expansion is unlikely to be as good as we previously believed. We exited our position.

30-Jun-2022 - Sebastien Mallet, Portfolio Manager, Global Value Equity Fund,

The portfolio's performance was boosted by the holding in Tongcheng Travel. The company's most recent results pleased investors, beating consensus expectations. Longer term, we continue to like company as we believe it is in a strong position to capture the rapid growing travel demand of users in lower-tier cities in China. In our view, current expectations for the reopening of the economy are low and that the risk-reward profile for the name from here is attractive.
Our avoidance of Amazon was also beneficial to relative returns as shares in the online retail giant dropped sharply.� Investors were concerned by both weak quarterly results and disappointing guidance.
Shares in global internet conglomerate Prosus rose strongly over the quarter. In previous months, the stock had been weak, reflecting to a large extent the fortunes of Tencent, the China-based IT conglomerate of which it is a major shareholder. Shares in the latter had come under significant pressure over the period on fears of further regulatory tightening by Chinese authorities, sending the shares to historic lows.
Our holding in UnitedHealth Group was beneficial. Having underperformed in 2021 as investors focused on growth names and uncertainty about health care reforms, shares in U.S.-based managed care company outperformed over the review period.� Investors were encouraged by strong earnings growth and raised guidance.
AstraZeneca was another outperformer over the quarter. The market was encouraged by quarterly earnings and revenues, which both came in ahead of consensus expectations. Forward guidance for the full year was reiterated, further reassuring investors.
Having no exposure to Nvidia served the portfolio well. The software and semiconductor company derives a substantial proportion of its revenue from its semiconductor chips used in consumer-oriented markets, particularly gaming, which are showing signs of weakness.
Shares in L3Harris Technologies outperformed both its sectoral peers and the broader benchmark index over the quarter. The company pleased investors with quarterly earnings which beat expectations, driven by stronger margins, and a maintenance of full-year guidance. L3Harris is engaged in the provision of defense and commercial technologies across the air, sea, space, and cyber domains, with the majority of its sales to the U.S. government, with approximately 20% of sales to commercial and other customers. As a technology-centric company, we believe it stands to be a beneficiary of the Department of Defense's prioritization of heavy investment in technology and connectivity.
Yangzijiang Shipbuilding was another key contributor to relative gains. Its shares were beneficiaries towards the general upswing in Chinese stocks over the period as well as growing hopes that global shipping demand will recover following a decade long bear market for the shipbuilding industry.
In contrast, our position in General Electric held back portfolio returns. A combination of macroeconomic pressures and supply chain issues led to downwards earnings revisions. Uncertainty around the upcoming split of the company into three separate entities focused on energy, aviation, and health care, also weighed on the stock.
Shares in Air Canada tumbled. The airline has struggled to recover from the pandemic-related slump in travel demand. More recently, rising fuel costs, fears that a slowing economy will lead to a cut in discretionary spending, and well-publicized flight delays and cancellation issues caused by staff shortages, have put fresh pressure on the stock.
The portfolio's position in Walmart hindered portfolio returns. The stock sold off sharply after the retailer released disappointing quarterly earnings, with the company citing a number of factors including higher wage expenses, fuel cost rises, and increased inventory. Investors were also disappointed by a cut in full-year profits guidance.

Benchmark Data Source: MSCI. MSCI index returns are shown with reinvestment of dividends after the deduction of withholding taxes. MSCI and its affiliates and third party sources and providers (collectively, “MSCI”) makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other indices or any securities or financial products. This report is not approved, reviewed, or produced by MSCI. Historical MSCI data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. None of the MSCI data is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such.

Past performance is not a reliable indicator of future performance.

Source for performance: T. Rowe Price. Fund performance is calculated using the official NAV with dividends reinvested, if any. The value of an investment and any income from it can go down as well as up. Investors may get back less than the amount invested. It will be affected by changes in the exchange rate between the base currency of the fund and the subscription currency, if different. Sales charges (up to a maximum of 5% for the A Class), taxes and other locally applied costs have not been deducted and if applicable, they will reduce the performance figures.

Daily performance data is based on the latest available NAV.

The Funds are sub-funds of the T. Rowe Price Funds SICAV, a Luxembourg investment company with variable capital which is registered with Commission de Surveillance du Secteur Financier and which qualifies as an undertaking for collective investment in transferable securities (“UCITS”). Full details of the objectives, investment policies and risks are located in the prospectus which is available with the key investor information documents and/or key information document (KID) in English and in an official language of the jurisdictions in which the Funds are registered for public sale, together with the articles of incorporation and the annual and semi-annual reports (together “Fund Documents”). Any decision to invest should be made on the basis of the Fund Documents which are available free of charge from the local representative, local information/paying agent or from authorised distributors. They can also be found along with a summary of investor rights in English at www.troweprice.com. The Management Company reserves the right to terminate marketing arrangements.

Please note that the Fund typically has a risk of high volatility.

Hedged share classes (denoted by 'h') utilise investment techniques to mitigate currency risk between the underlying investment currency(ies) of the fund and the currency of the hedged share class. The costs of doing so will be borne by the share class and there is no guarantee that such hedging will be effective.

The specific securities identified and described in this website do not represent all of the securities purchased, sold, or recommended for the sub-fund and no assumptions should be made that the securities identified and discussed were or will be profitable.

Attribution Data: Analysis represents the total performance of the portfolio as calculated by the FactSet attribution model and is inclusive of other assets that that will not receive a classification assignment in the detailed structure shown. Returns will not match official T. Rowe Price performance because FactSet uses different exchange rate sources and does not capture intra-day trading. Performance for each security is obtained in the local currency and, if necessary, is converted to U.S. dollars using an exchange rate determined by an independent third party. Figures are shown with gross dividends reinvested.

Sources: Copyright © 2021 FactSet Research Systems Inc. All rights reserved. MSCI/S&P GICS Sectors; Analysis by T. Rowe Price Associates, Inc. T. Rowe Price uses the MSCI/S&P Global Industry Classification Standard (GICS) for sector and industry reporting. Each year, MSCI and S&P make changes to the GICS structure. The last change occurred on September 28, 2018. T. Rowe Price will adhere to all future updates to GICS for prospective reporting.

The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property and a service mark of Morgan Stanley Capital International Inc, ("MSCI") and Standard & Poor's, a division of The McGraw-Hill Companies, Inc. ("S&P") and is licensed for use by [Licensee]. Neither MSCI, S&P nor any third party involved in making or compiling the GICS or any GICS classifications makes any express or impIied warranties or representations with respect to such standard or classification (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability and fitness for a particular purpose with respect to any or such standard or classification, Without limiting any or the foregoing, in no event shall MSCI, S&P, any of their affiliates or any third party involved in making or compiling the GICS or any GICS classifications have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

A full list of the currently issued Share Classes including Distributing, Hedged, and Accumulating Categories may be obtained, free of charge and upon request, from the registered office of the Company.

The Morningstar rating is sourced from Morningstar.

©2022 Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

Citywire Data Source: Citywire – where the fund manager is rated by Citywire, the rating is based on the manager’s 3-year risk adjusted performance. For further information on ratings methodology, please visit www.aboutcitywire.com.

Financials

Health Care

IT

Japan

Risks

Typical Investor